This book deals with the emerging concept that certain pathogenic bacteria and viruses, when infecting people with cancer, actively fight tumors, allowing their regression. Although such observations go back more than 100 years, use of specific bacterial strains, or viruses, usually genetically modified with known anticancer drugs, and their protein/peptide products, has gained ground in recent years, allowing significant cancer regression in clinical trials with stage III/IV cancer patients or even in pediatric brain tumor patients, often without any demonstration of toxicity. It is composed of 12 chapters written by pioneers in microbial, biotech, and cancer research and covers the emerging roles of various microorganisms and their products in cancer therapy. The book highlights the benefits of using conventional cancer treatments (such as chemo- and radiotherapies) with microbial-based therapies. Such combinatorial therapies have gained particular attention as a strategy to overcome drug resistance, and the readers of the book will discover their impact on fundamental research and promising results from clinical trials.

Bifidobacterium as a Delivery System of Functional Gene for Cancer Gene Therapy
Therapy with Oncolytic Clostridium novyi-NT: From Mice to Men
Genetic Engineering of Clostridial Strains for Cancer Therapy
Bacteria-Derived Alternatives to Live Mycobacterium bovis Bacillus Calmette-Guerin for Non-Muscle Invasive Bladder Cancer Treatment
Genetically Modified Salmonella as Cancer Therapeutics: Mechanisms, Advances and Challenges
Genetically Engineered Oncolytic Salmonella typhimurium
Engineering E. coli to Combat Cancer
Live P. aeruginosa as Cancer Vaccine Vector
The Anticancer Potential of the Bacterial Protein Azurin and Its Derived Peptide P28
Bacteriocins: From Antimicrobial to Potencial Anticancer Agents
Bacteriocins as Anticancer Peptides? A Biophysical Approach
Where Cancer and Bacteria Meet